The tender covers about 80 percent of Brazil’s public trastuzumab market. Herzuma leads Brazilian prescriptions with about 50 percent market share, ahead of the original drug, according to IQVIA data cited by Celltrion.
Celltrion is also adding more drugs in Brazil.
Omlyclo, its omalizumab biosimilar, has taken about 26 percent of the private market since launching late last year. Eye treatment Eydenzelt and autoimmune drug Avtozma are set to launch by year-end.
Tags: Celltrion, Biosimilar, Brazil, Omlyclo, Eydenzelt, Avtozma, IQVIA, Market Share
Copyright ⓒ Aju Press All rights reserved.
